Wing Yeung
Senior Marketing Manager
Genentech
Pegah Moghaddam
Senior Marketing Manager
Genentech
Partnering to Take on the Flu Season
When launching a new treatment to managed care stakeholders, no duo is better suited to the task than Wing Yeung and Pegah Moghaddam. In November of 2018, Wing and Pegah successfully launched the influenza treatment XOFLUZATM (baloxavir marboxil) with style, grace, and ease. XOFLUZA is a single-dose, oral treatment for acute, uncomplicated influenza in patients 12 years and older. It received Priority Review by the FDA, a designation granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention, or diagnosis of a disease.
After a particularly severe 2017-2018 flu season, Wing and Pegah developed a managed care launch strategy for the first flu medicine with a novel proposed mechanism of action in nearly 20 years. Tasked with the important job to launch XOFLUZA to managed care customers, Wing and Pegah created tailored resources and engagement opportunities to ensure a smooth launch. They also collaborated with multiple field teams to ensure appropriate execution of the strategy as XOFLUZA hit the market.
Wing and Pegah’s leadership allowed for all the different teams and agencies supporting XOFLUZA to carry out a consistent launch campaign for the new influenza treatment. Under their leadership, launch materials were created and disseminated to key managed care players to ensure patient access of XOFLUZA as it entered the market in November. Thanks to Wing and Pegah, future flu seasons look a little bit brighter!
